Drug intelligence / Profile preview

PRO95780 + FOLFIRI + bevacizumab

Development stage: Unknown
Lead developer: Genentech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

**PRO95780 + FOLFIRI + bevacizumab** is an investigational combination therapy studied primarily in advanced metastatic colorectal cancer. It consists of: - **PRO95780** (a code-named experimental antibody targeting death receptor 5) - **FOLFIRI**, a chemotherapy regimen including folinic acid (leucovorin), fluorouracil, and irinotecan - **bevacizumab**, a monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A) **PRO95780** acts through apoptosis induction in cancer cells by activating death receptor 5. **FOLFIRI** consists of agents that interfere with DNA synthesis and replication, exerting cytotoxic effects on cancer cells. **Bevacizumab** inhibits angiogenesis by neutralizing VEGF-A. This combination is being explored for synergistic anticancer effects in patients who have failed previous treatments, notably for metastatic colorectal cancer[5][7][8][9].

Other names: PRO95780 + FOLFIRI + bevacizumabFOLFIRI-bevacizumab + PRO95780

Targets

TNFRSF10B (DR5)TS (Thymidylate synthase)TOP1 (DNA Topoisomerase I)DHFR (Dihydrofolate reductase)VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on PRO95780 + FOLFIRI + bevacizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PRO95780 + FOLFIRI + bevacizumab.

Explore the full profile